Canada’s Digital Technology Supercluster officially launches with $153M in funding from the Ministry of Innovation, Science and Economic Development and funding commitments of over $200M from members

December 5, 2018
Canada’s Digital Technology Supercluster

Vancouver – November 27, 2018 – Canada’s Digital Technology Supercluster is excited to announce its official launch and celebrate the funding allocation by the Ministry of Innovation, Science, and Economic Development (ISED) and funding commitments by its initial cohort of members. The Government of Canada is investing up to $950 million over five years to … Continue reading Canada’s Digital Technology Supercluster officially launches with $153M in funding from the Ministry of Innovation, Science and Economic Development and funding commitments of over $200M from members

Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting

December 3, 2018
Xenon Pharmaceuticals Inc.

XEN1101 CTA Accepted by Health Canada for Initiation of Phase 2 Clinical Trial in Adult Focal Epilepsy; U.S. IND Filing Targeted in Q1 2019 Conference Call to Discuss Xenon’s Epilepsy Programs at 9 am ET Today BURNABY, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today … Continue reading Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting

Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting

November 30, 2018
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Nov. 30, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Monday, December 3, 2018 at 9:00 am Eastern Time (6:00 am Pacific Time) to provide a corporate update and overview of the Company’s poster … Continue reading Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting

INSTI HIV Self Test Earns WHO Prequalification Status for Home Testing

November 28, 2018
bioLytical Laboratories Inc.

The newly WHO Prequalified INSTI HIV Self Test makes a mark as it expands into new markets VANCOUVER, BC, November 28, 2018 /CNW/ – bioLytical Laboratories, a world leader in rapid infectious disease tests, is pleased to announce that its INSTI® HIV Self Test has been Prequalified  by the World Health Organization (WHO).  INSTI, the world’s fastest home … Continue reading INSTI HIV Self Test Earns WHO Prequalification Status for Home Testing

Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors

November 27, 2018
Arbutus Biopharma Corporation

WARMINSTER, Pa., Nov. 26, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Frank Torti has been appointed as Chairman of the Company’s Board of Directors, effective November 26, 2018. “We are pleased to welcome Frank to our Board,” said Dr. Mark J Murray, President and CEO of Arbutus. … Continue reading Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors

DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting

November 20, 2018
DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 20, 2018 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, presented scientific updates, including data from two ongoing clinical trials, at the 23rd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) … Continue reading DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting

ASPECT BIOSYSTEMS RECEIVES $2.7M INVESTMENT FROM THE GOVERNMENT OF CANADA

November 15, 2018

Government of Canada invests nearly $20M in top British Columbia companies in 2018 VANCOUVER, British Columbia – November 15, 2018 – Aspect Biosystems, a leader in the field of 3D bioprinting and tissue engineering, has received $2.7 million from the Government of Canada’s Western Innovation (WINN) Initiative. WINN has funded 17 projects in British Columbia … Continue reading ASPECT BIOSYSTEMS RECEIVES $2.7M INVESTMENT FROM THE GOVERNMENT OF CANADA

Zucara Therapeutics – Helping people with diabetes sleep safely and soundly

Zucara Therapeutics Inc.

Typically occurring overnight, hypoglycemia puts over 8 million people with diabetes at fatal risk during their sleep Current therapies offer hypoglycemic treatment only once an episode occurs Zucara is working on the first treatment to prevent hypoglycemia which can kill patients in their sleep November 14, 2018 – Vancouver, Canada: On World Diabetes Day, Zucara … Continue reading Zucara Therapeutics – Helping people with diabetes sleep safely and soundly

Precision NanoSystems and Entos Pharmaceuticals sign license agreement for the use of the NanoAssemblr® platform for scale-up and GMP manufacturing of nanomedicines

November 14, 2018
Precision NanoSystems Inc.

VANCOUVER , BC- November 13, 2018 Precision NanoSystems, Inc. (PNI) and Entos Pharmaceuticals (Entos) today announced they have entered into a license and supply agreement whereby PNI will provide its scale-up system, technology transfer and support the GMP manufacturing of Entos’ lead candidate. Entos will use the NanoAssemblr Blaze™ instrument for preclinical toxicology studies and transition … Continue reading Precision NanoSystems and Entos Pharmaceuticals sign license agreement for the use of the NanoAssemblr® platform for scale-up and GMP manufacturing of nanomedicines

Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium

Zymeworks Inc.

ZW25 Active and Well Tolerated Across Multiple HER2-expressing Tumor Types Durable Anti-Tumor Activity with Confirmed Partial Responses and Median Progression-Free Survival > Six Months 82 Percent of Heavily Pretreated Patients Experienced Disease Control DUBLIN–(BUSINESS WIRE)– Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today the plenary presentation of updated ZW25 clinical … Continue reading Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium